Literature DB >> 12364472

Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma.

Anne-Paule Gimenez-Roqueplo1, Judith Favier, Pierre Rustin, Claudine Rieubland, Véronique Kerlan, Pierre-François Plouin, Agnès Rötig, Xavier Jeunemaitre.   

Abstract

Three genes encoding for mitochondrial complex II proteins are linked to hereditary paraganglioma. We have recently shown that an inactivation of the SDHD gene is associated with a complete loss of mitochondrial complex II activity and a stimulation of the angiogenic pathway (Gimenez-Roqueplo, A. P., J. Favier, P. Rustin, J. J. Mourad, P. F. Plouin, P. Corvol, A. Rötig, and X. Jeunemaitre, 2001, Am J Hum Genet 69:1186-1197). Here, we relate the case of a malignant sporadic pheochromocytoma induced by a germline missense mutation of the SDHB gene. Within the tumor, a loss of heterozygosity at chromosome 1pter led to a null SDHB allele and to a complete loss of complex II enzymatic activity. In situ hybridization and immunohistochemistry experiments showed a high expression of hypoxic-angiogenic responsive genes, similar to that previously observed in inherited-SDHD tumors. This observation highlights the role of the complex II mitochondrial genes in the oxygen-sensing pathway and in the regulation of angiogenesis of neural crest-derived tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12364472     DOI: 10.1210/jc.2002-020525

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  76 in total

1.  Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.

Authors:  Montserrat Ayala-Ramirez; Lei Feng; Mouhammed A Habra; Thereasa Rich; Paxton V Dickson; Nancy Perrier; Alexandria Phan; Steven Waguespack; Shreyaskumar Patel; Camilo Jimenez
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

2.  Malignant paraganglioma of the urinary bladder: Immunohistochemical study of prognostic indicators.

Authors:  Kalman Kovacs; David Bell; Geoffrey W Gardiner; R John Honey; Jeannette Goguen; Fabio Rotondo
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  Succinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome.

Authors:  Nikolaos Settas; Fabio R Faucz; Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2017-07-21       Impact factor: 4.102

Review 4.  Pheochromocytoma: The First Metabolic Endocrine Cancer.

Authors:  Ivana Jochmanova; Karel Pacak
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

Review 5.  Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background.

Authors:  Lauren Fishbein; Katherine L Nathanson
Journal:  Cancer Genet       Date:  2012 Jan-Feb

Review 6.  Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options.

Authors:  Svenja Nölting; Ashley Grossman; Karel Pacak
Journal:  Exp Clin Endocrinol Diabetes       Date:  2018-09-20       Impact factor: 2.949

Review 7.  Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel.

Authors:  Andrew P Wojtovich; C Owen Smith; Cole M Haynes; Keith W Nehrke; Paul S Brookes
Journal:  Biochim Biophys Acta       Date:  2013-01-02

8.  Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.

Authors:  Esmeralda Castelblanco; Maria Santacana; Joan Valls; Aguirre de Cubas; Alberto Cascón; Mercedes Robledo; Xavier Matias-Guiu
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

9.  Familial paragangliomas.

Authors:  Cjm Lips; Egwm Lentjes; Jwm Höppener; Rb van der Luijt; Fl Moll
Journal:  Hered Cancer Clin Pract       Date:  2006-10-15       Impact factor: 2.857

Review 10.  Mitochondrial disorders.

Authors:  Massimo Zeviani; Antonella Spinazzola
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.